Given our proven and extensive expertise in the discovery of new antiviral therapies, and recognizing the global urgency in developing therapeutics to address coronaviral infections, we have initiated a drug discovery effort to develop new pan-coronavirus direct-acting antivirals to treat COVID-19 and future coronavirus outbreaks.


At this time, our COVID-19 research program is focused on the discovery and development of new small molecules that address specific viral targets including the nsp12 viral polymerase and the nsp5 viral protease, both of which are essential viral proteins across the entire pan-coronavirus spectrum. We are rapidly progressing lead candidates to nomination in this program.